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Digoxin, the cardiac glycoside most frequently used in clinical practice in the United States, can be given orally or intravenously and has an excretory half-life of 36 to 48 hours in patients with serum creatinine and blood urea nitrogen values in the normal range. Since the drug is excreted predominantly by the kidney, the half-life is prolonged progressively with diminishing renal function, reaching about 5 days on average in patients who are essentially anephric. Serum protein binding of digoxin is only about 20%, and differs markedly in this regard from that of digitoxin, which is 97% bound by serum albumin at usual therapeutic levels. Digitoxin is nearly completely absorbed from the normal gastrointestinal tract and has a half-life averaging 5 to 6 days in patients receiving usual doses irrespective of renal function. The
Pharmacokinetics
Preparations of cardiac glycosides used clinically are derived from the leaves and seeds of plants from the genera Digitalis and Strophanthus. Other flora contain cardiac glycosides that may be of importance with regard to toxicity, but are not used clinically. These include Convallaria majalis (lily of the valley) and Thevetia neriifolia (yellow oleander) .
All of the cardiac glycosides consist of combinations of an aglycone , or genin , with one to four attached sugar residues . The characteristic pharmacologic properties reside in the genin , while factors influencing pharmacokinetic properties , including water solubility, are influenced by the nature of the sugars (glycosides) attached to the genin. Figure I outlines the derivation of the cardiac glycosides currently in clinical use in the United States. Leaves from the Digitalis lanata plant contain precursor glycosides that yield digitoxin and digoxin after minor chemical derivation (1) . The seeds of Strophanthus gratus contain ouabain . bioavailability of digoxin is appreciably less than that of digitoxin, averaging about two-thirds to three-fourths of the equivalent dose given intravenously in the case of currently available tablet formulations. Recent studies have shown that gut ftora of about 10% of patients reduce digoxin to a less bioactive dihydro derivative. This process is sensitive to antibiotic administration, creating the potential for important interactions among drugs. Serum or plasma concentrations of digitalis glycosides can be measured by radioimmunoassay methods that are now widelyavailable, but knowledgeof serum levelsdoes not substitute for a sound working knowledge of the clinical pharmacology of the preparation used and careful patient follow-up. 
Digoxin
Routes of administration. Digoxin is the form of digitalis most frequently used in the United States, both in hospital and office practice. This is probably due in large part to its flexible routes of administration, its intermediate duration of action and the availability of convenient methods for assaying serum digoxin concentrations. Although digoxin may be administered orally , intravenously or intramuscularly , the intramuscular route is not recommended because it is painful and produces localized muscle damage reflected in increased serum creatine kinase levels . The classic studies of the pharmacokinetics of digoxin carried out by Dohert y et al. (2) established the patterns observed after use of these three routes of administration in volunteers with normal renal function (Fig. 2) . As expected, the serum concentration rises most rapidly after intravenous administration , followed by oral and , still later , by intramuscular administration .
Excretion. Excretion of digoxin occurs at a rate independent of the route of administration. Digoxin is excreted in an exponential manner, with an average half-life of 36 hours in healthy individual s with normal renal function (3) . Approximately 37% of total body stores of digoxin are excreted daily under these circumstances. Older patients usually have a reduced glomerular filtration rate even if the blood urea nitrogen and creatinine levels remain in the normal range, and a half-life of 48 hours represents a more reasonable estimate. Renal excretion of digoxin tends to be independent of the rate of urinary flow in patients with reasonably normal renal function (4, 5) . There is, however, some dependence of renal tubular reabsorption of digoxin on the urinary flow rate, and hence digoxin reabsorption ruay increase at very low rates of urinary flow and conversely may be decreased by acute vasodilator therapy in patients with congestive heart failure (6,7). Digoxinexcretion by way of the kidney is predominantly in an unchanged to.rn, but a subset of about 10% of patients excrete appreciable quantitiesof relatively inactivemetabolites (8) . Equilibrium or steady state conditions occur at the point when daily losses of digoxin through renal and other pathways match the daily intake of the drug.
Absorptioh. A useful clinical principle is that when daily maintenance therapy is begun in patients not previously receiving digoxin, steady state plateau concentrations exist after four to five half-lives or about 7 days in patients with normal renal function (9) . In the presence of renal impairment resulting in prolongation of the half-lifeof elimination, the time required to reach steady state on a daily maintenance regimen is correspondingly prolonged. When rapid onset of digoxin effect is needed, a loading dose is administered. followed by daily maintenance therapy. In obese subjects, digoxin pharmacokinetics change little after the loss of large amounts of adipose tissue, indicating that lean body mass should be used when dosages are calculated (10, 11) .
Nomograms for calculationof the total oral loading dose and daily maintenance dose of digoxinbasedon body weight and renal function are available (12) . Such nomograms are helpful for the initial estimation of digoxin dosage, but do not change the need for careful follow-up by the clinician.
Gastrointestinal absorption ofdigitalis glycosides is passive . The rate and completeness of absorption are greatest with the least polar molecules and decrease with increasing cardiac glycoside polarity (13) . Patients with normal gastrointestinal function shouldabsorbdigoxin administered by the oral route at about 85% of the administered dose in elixir form and 60 to 75% in tablet formulations that meet current Food and Drug Administration and United States Pharmacopeia guidelines (14) (see subsequent comments on bioavailability).
Protein binding of digoxin averages 20 to 25% under usual circumstances (15, 16) . Only the free fraction is pharmacologically active. In the case of digoxin, proteinbinding is a minor factor in determining the pharmacokinetics because glomerularfiltration of the drug should be about 80% of the serum concentration. ., "
Time course of digoxin distribution in the body. The time course is well characterized by a two compartment model (2) . Distribution from the central (vascular) compartment to peripheral sites occurs with a half-time of about 30 minutes. Although the concentration of digoxin in skeletal muscle is relatively low compared with that in the kidney or heart, the total digoxin content of skeletal muscle represents the largest single pool in the body because of the large mass of this component of body composition. Available studies (17) demonstrate a fairly constant ratio between the digoxin bound to heart muscle and the serum concentration. It is of importance, however, that electrolyte derangements can exert clinically significant effects on myocardial uptake and distribution of cardiac glycosides. Hyperkalemia and hyponatremia reduce digoxin binding to the myocardium (4, 18) . Important interactions among drugs affect the distribution of digoxin in the body, as discussed elsewhere in this symposium (19) .
Absorption and excretion in infants. Infants and children usually absorb and excrete digoxin in a manner similar to that of adults. Nevertheless, digoxin doses in infants characteristically are larger than those conventionally used in adults when calculated on the basis of mg/kg of body weight or per unit of body surface area. These higher doses tend to produce higher serum digoxin concentrations, which are usually well tolerated (20) (21) (22) . Digoxin crosses the placental barrier, as documented by the observation (20) that fetal umbilical cord digoxin concentrations are comparable with those found in the venous blood of the mother at term.
Metabolism of digoxin. Although renal excretion of di-
goxin is the dominant route of elimination, digoxin is metabolized to some degree to reduced compounds such as dihydrodigoxin and dihydrodigoxigenin (2) . In certain individuals (about 10% of most patient groups), such metabolism accounts for up to 30 to 40% of the total urinary excretion of digoxin and its metabolites (8, 23) . The work of Lindenbaum et al. (24) established that the metabolism of digoxin to reduce products varies both with the bioavailability of the drug and with the nature of the bacterial flora in the gastrointestinal tract. Consequently, antibiotic therapy that changes the flora reduces the metabolism of digoxin to inactive products and can produce an apparent increase in the effective amount of drug in the body when the intake of digoxin remains constant. Particular care is needed in the surveillance of patients receiving digoxin when antibiotics are added to the regimen. Data regarding the pharmacokinetics of digoxin and other clinically relevant glycosides are summarized in Table I .
Digitoxin
Half-life of elimination. Although it is the second most frequently prescribed cardiac glycoside in the United States, digitoxin is far less commonly used than digoxin. It is less polar than any other glycoside in current use and, therefore, binds avidly to serum proteins. This results in very limited renal excretion, and the half-life of elimination of digitoxin accordingly varies littie from the average of 4 to 6 days, irrespective of renal status (15) . Because of the longer halflife, initiation of daily maintenance doses of digitoxin will not produce steady state levels until about 3 to 4 weeks. The bioavailability of digitoxin when administered orally approaches 100% (25) .
As stated, digitoxin binds avidly to human serum albumin such that about 97% of the drug circulates in a bound state under usual clinical circumstances. A number of drugs are reported (26) to displace digitoxin from serum albumin binding sites, but it is not clear if these interactions are of clinical importance. It may be that severe depletion of serum albumin (for example, in nephrotic syndrome) may effectively increase the effect of digitoxin at any given total serum concentration of the drug.
Mode of elimination. The major route of elimination of digitoxin is metabolism in the liver. Approximately 8% of the body digitoxin store undergoes biotransformation to metabolites, some of which are cardioactive and some of which are not (27, 28) . Enterohepatic cycling of digitoxin averages approximately 6 to 7%/day (29) . This cycle can be interrupted at least in part by nonabsorbable resins, such as cholestyramine, that bind digitoxin in the gut (30) . This tends to enhance the clearance rate, although it is not Clear that the effect is sufficient to be decisive in the management of overt digitoxin toxicity.
Other Cardiac Glycosides
Deslanoside (Cedilanid-D), This glycoside is structurally similar to digoxin, but has an additional glucose residue attached to the terminal sugar. This results in markedly decreased gastrointestinal absorption, and deslanoside is used very little in the United States at the present time. Its excretion kinetics are very similar to those of digoxin (2) .
Ouabain. This is the most polar of the clinically available cardiac glycosides, and is only used intravenously for rapid digitalization. It is excreted by exponential or firstorder kinetics, predominantly through the kidney. Patients with normal renal function have a serum ouabain half-life averaging 21 hours. As with digoxin, impaired renal function will slow the excretion of ouabain (31) .
Information on the pharmacokinetics of other glycosides not commonly used in the United States is discussed in appropriate review articles (17) .
Bioavailability
Factors affecting digoxin absorption. Observations in the 1970s led to the conclusion that some patients had low serum digoxin concentrations and responded poorly to the drug despite relatively large oral doses (32) . This prompted the investigation of the bioavailability of several digoxin preparations. Although various pharmaceutical formulations may contain chemically equivalent amounts of digoxin, studies (32) have shown a wide range of dissolution rates of available marketed digoxin tablets from several suppliers. This, together with individual patient variation, can result in substantial variability in digoxin bioavailability. Malabsorption syndromes may also produce poor and erratic digoxin absorption (33), although maldigestion caused by pancreatic insufficiency usually results in normal absorption of the drug. Digoxin ingestion along with or shortly after meals tends to decrease the peak serum concentration, but total absorption is not appreciably reduced in patients with normal gastrointestinal function (34) . Digoxin absorption tends to be enhanced by drugs that reduce the motility of the gastrointestinal tract, and conversely can be decreased by drugs that increase motility (35) . Certain nonabsorbable substances, including cholestyramine, colestipol, kaolin-pectin and nonabsorbable antacids, can interfere with gastrointestinal absorption of digoxin when taken concurrently (17) . The antibiotic neomycin has also been shown to interfere with digoxin absorption (36).
Clinical implications. Bioavailability considerations have
important clinical implications given the relatively narrow margin between therapeutic and toxic digoxin doses and serum levels. Current FDA and USP bioavailability guidelines include defined permissible ranges of tablet dissolution rates, and require the demonstration in human subjects that such dissolution rate data translate into clinically reliable bioavailability (37) . Current FDA guidelines require that all digoxin tablets marketed in the United States must have an in vitro dissolution rate of at least 65% in I hour, but no greater than 90% in 15 minutes. Digoxin elixir is more bioavailable (70 to 85% of the intravenous dose) than the usual tablet form (60 to 80% of the intravenous dose) (38, 39) . A recently marketed digoxin gel solution in capsules (Lanoxicaps, Burroughs-Wellcome Co.) has enhanced bioavailability (90 to 100%) compared with tablets, elixir or intramuscular preparations. The clinician should be aware that early high serum digoxin concentrations occur after ingestion of the encapsulated gel formulation. Because of the greater bioavailability, Lanoxicaps of 0.1 and 0.2 mg strength are approximately equivalent to tablets with a strength of 0.125 and 0.25 mg, respectively.
As emphasized elsewhere in this symposium (19) , clinicians must be alert to alterations in the total medication program of the patient because addition or discontinuation (40) . Each method has its specific advantages and disadvantages. The radioimmunoassay technique (41) is now used in most clinical laboratories . Digoxin and digitoxin concentrations in serum can be determined separately given appropriate attention to technical details. However, radioimmunoassay techniques in general have a variety of pitfalls, and the clinical usefulness of serum concentrations is limited by the accuracy of the reported values. Proper selection of the antibody population, accuracy of standards, purity of tracer glycosides and care in the use of counting methods are all requisite to obtaining satisfactory results. The presence in serum of diagnostic radioisotopes used in nuclear medicine scanning techniques can be misleading. In addition, the clinician must avoid drawing blood samples for cardiac glycoside analysis shortly after doses so that full equilibration of the drug between the plasma and the heart and other body compartments is complete. Sampling of serum should generally be done at least 5 to 6 hours after either oral or intravenous doses.
Rationale for serum digitalis measurements. Several lines of evidence bear on the relation between serum glycoside levels and the corresponding pharmacologic effect. Both therapeutic and toxic effects of cardiac glycosides are dose-related. All studies demonstrate that serum glycoside levels increase with increasing dosage, and a statistical correlation between serum level and clinical state would, therefore, be anticipated. Experimental and clinical studies (42, 43) demonstrate a relatively constant ratio of serum to myocardial digoxin concentrations after full equilibration between vascular and peripheral compartments. Since the cardiac glycoside binding site of the receptor Na-K adenosine triphosphatase (ATPase) faces the outer cell surface, a basis exists for the translation of serum level to effect on the myocardial cell. Perhaps most importantly, experimental studies (44) have shown a predictable relation between serum digoxin concentration and cardiac electrophysiologic effects.
Although true in a general sense, these considerations leave room for substantial variability in the response of the individual patient to a given serum digitalis level. The study of Klein et al. (45) , in which serum digoxin levels were correlated with acetylstrophanthidin tolerance, demonstrated that severe pulmonary, coronary and aortic valve disease, as well as old age, predisposed patients to cardiac glycoside sensitivity. Other variables influencing individual patient sensitivity to cardiac glycosides are discussed in detail elsewhere in this symposium (46) .
Clinical correlations of serum digitalis levels.
Approximately 50 studies correlating serum digitalis levels with clinical state have been published and have been reviewed recently (17) . These are summarized briefly in Tables 2 and 3. The findings from these studies, based on data from more than 1,000 patients, indicate that the serum digoxin level in patients receiving therapeutically appropriate doses averages about 1.4 ng/ml (1.8 nmol/liter), while mean levels in patients with drug toxicity, as defined by the presence of typical arrhythmias, are generally higher by a factor of 2 to 3. Although this difference is statistically significant in the vast majority of studies, overlap clearly does exist between serum digoxin levels in groups of patients with and without toxicity. Such overlap is generally more pronounced in prospective blind study protocols than in unblinded retrospective studies (47) .
Extensive data are also available for patients receiving digitoxin ( Table 3) . Digitoxin levels in serum or plasma are higher than those of digoxin by a factor of about 10 because of substantial serum protein binding of digitoxin as just discussed. The results of studies of clinical correlations are otherwise analogous to those for digoxin in that mean levels observed for groups of patients considered to be optimally digitalized are significantly less than values for patients with overt toxicity. Again, substantial overlap exists between groups with and without toxicity.
In terms of the management of individual patients, I would emphasize that no specific serum concentration exists that can be used to define a clear boundary between the presence and absence of toxicity. A particular problem in this regard is the definition of digitalis toxicity because abnormalities of cardiac impulse formation or conduction resulting from digitalis excess also occur as a consequence of intrinsic heart disease, even in patients without prior digitalis exposure. Consequently, serum digitalis levels should be considered together with all of the additional clinical data available before a clinical management decision is reached.
Optimal serum glycoside levels. It is no easy matter to establish optimal serum cardiac glycoside levels, even in patients with no evidence of toxicity. Chamberlain et al. (48) observed a correlation, within broad limits, between serum digoxin concentrations and the ventricular rate in the presence of atrial fibrillation, at least in patients who had relatively rapid ventricular rates before administration of digitalis. It is commonly found that "therapeutic" digoxin levels are inadequate to control the ventricular rate in acutely ill patients with problems such as hypoxia, infection or recent surgery. In the study by Goldman et al. (49), serum digoxin levels of +.5 ng/ml or greater were required to control the ventricular response in 15 of 39 patients. The current availability of beta-adrenergic blocking agents and verapamil usually obviates the need for the use of unusually large doses of digitalis to control the ventricular response in the presence of supraventricular tachyarrhythmias.
A particularly difficult question relates to the definition of optimal serum glycoside concentrations ill patients with congestive heart failure and normal sinus rhythm. Although the available data are somewhat limited, recent studies (17) suggest that the favorable hemodynamic effects of digoxin may tend~o plateau at serum levels in the range of 1.0 to 1.5 ng/rnl. It remains to be shown whether higher, serum levels will produce further enhancement of the contractile state. Thus, it may well be that the optimal risk-benefit ratio is achieved at serum levels in the 1.0 to 1.5 range. There is certainly no doubt that higher levels expose the patient to an increased risk of cardiac glycoside-induced rhythm disturbances.
Cost-effectiveness. The cost-effective clinical use of serum glycoside measurements, as with all laboratory tests, requires considerable sophistication on the part of the clinician. Evaluation of timing and magnitude of prior digoxin doses, renal function and body mass allows a first approximation of the body stores of the drug. When patients receiving maintenance digitalis develop symptoms such as fatigue, visual changes, anorexia, nausea, vomiting or cardiac arrhythmias, digitalis intoxication should be suspected and serum level data are likely to be of use. Serum digoxin levels within the range usually considered as "therapeutic"
should not be considered to exclude toxicity in view of the marked variability in individual patient responses. The nature and severity of underlying heartdisease are particularly important variables.
Failure to achieve adequate therapeutic response.
Another common clinical problem is the failure to achieve an adequate therapeutic response in a patient receiving conventional digoxin doses. It must be determined whether the dose is inadequate (for example, as a result of impaired gastrointestinal absorption or noncompliance with a prescribed regimen) or whether there are reasons why the patient may be relatively resistant to usual digoxin doses and serum levels (for example, occult thyrotoxicosis or mitral stenosis). If the patient is taking the prescribed dose and the serum digoxin level remains low, this information may provide the clue to other clinical disorders or drug interactions. Hyperthyroidism tends to produce relatively low serum digoxin concentrations in addition to true resistance to control of the ventricular response to atrial fibrillation typical of this condition. Malabsorption syndromes andpoorly bioavailable digoxin preparations will result in low serum digoxin concentrations and clinical signsof inadequate digitalization. Drug interactions, as discussed elsewhere (19) , can produce substantial variations in serum levels.
Lastly, skepticism is appropriate when laboratory results
conflict with clinical judgment. Underno circumstances can serum digitalis levels replace sound clinical judgment. Individual laboratory values should never be used as the sole basis for determining the presence of drug toxicity or efficacy. I do not advocate the periodic routine measurement of serum digoxin concentrations in patients with a satisfactory therapeutic response to a properly chosen dosage regimen. The best assurance of an optimal risk-benefit ratio will always be the careful follow-up of the patient by a vigilant clinician.
